EPZM - Epizyme Has One FDA Approval Down One More To Go In Coming Months
Epizyme (EPZM) announced that it had received accelerated FDA approval of TAZVERIK (tazemetostat) for the treatment of patients with epithelioid sarcoma. This drug, for this specific indication, is estimated to generate roughly $100 million. However, I'm more inclined to say that this approval isn't the only one that is possible for this year. That's because an NDA to the FDA was already submitted for possible approval of tazemetostat to treat patients with relapsed/refractory follicular lymphoma ((FL)). This sets up another catalyst in the coming months. That's because there will be a decision on the filing